AGP Executive Report
Last update: 4 hours agoMedical Tech in Europe: The European Commission cleared Gilead’s Trodelvy (sacituzumab govitecan) plus Keytruda for first-line metastatic triple-negative breast cancer in PD-L1 CPS≥10 tumors, and also expanded Trodelvy approvals across PD-L1 status. Rare Disease Treatment: Acadia’s DAYBU (trofinetide) won EU marketing authorization as the first and only approved treatment for Rett syndrome neurobehavioral symptoms in adults and children 5+. AI Advertising Rollout: ChatGPT Ads is set to launch in 31 European markets on Aug. 24, with ads shown only on Free and Go plans and no personalized ads in the EEA/Switzerland at launch. Drone Supply Chain Shock: New US Section 232 tariffs will hit imported drones and components from Sept. 3, with duties up to 100% for certain systems (including thermal imaging) and 25% for smaller drones. Sanctions Coordination: Eight non-EU countries, including Liechtenstein, agreed to align with the EU’s latest Belarus sanctions, expanding restrictions on military-tech and crypto-related activity. Liechtenstein in Finance: LGT pushed assets past CHF 400bn for the first time in H1 2026, driven by net inflows and Asia momentum.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
